{"ticker": {"uuid": "b06048fd-c640-4d3f-b067-fa83446836d3", "symbol": "ISOFOL", "name": "Isofol Medical AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Isofol begins final dose cohort on the way to Phase II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQcWJ1Vm9TeFVmOFpZNjc3b3FEMGNJSzl2V2NaLVBxZF90X3BvQXJUVHJZX1g2Sk1uN21QUGRnWGNad0E5dlFQR1ZGa04yZ1NVaVM1dy1jOWkzZ3AyM0lMVHRYVnNJZGN0Q3BTVy1oM3pVUWlvUTd6c2phSk5EdXlsZzg2OGtrTWJlMXc?oc=5", "source_name": "Biostock", "published_at": "2026-07-08T15:21:02+00:00", "published_display": "08 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol advances arfolitixorin trial with final dose cohort in colorectal cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQTFJhVkRKSGV1NVlpbHNfOFdMWEZxNlhRYS1SSkpxMl9QMjQzU1JZZERSQU8xdWRYRHM2WXRPOVRFYldYcGZLWHlOOHlwY2hKMXlCdFBfV2hrUExDcGc5d051WWFzRlRvQnlGenY3T1dqbnBCTjhsWXNlOGlkSEZxREZfNGJHRjlEaThSVHduMFZlUzAtNUw3VV81aDBZM2xMd293YXJEdk5DcmpVRGh6UFFtTjlPUTlMd2JHR0ZWRUVUVkhIR3gzXzVTcGNVUmlqZkpN?oc=5", "source_name": "TipRanks", "published_at": "2026-07-08T10:07:10+00:00", "published_display": "08 Jul 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Isofol Medical (STO:ISOFOL) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPNTNQZ2wwSGFuT0MxVUtpX0lpQUxyQTFleU1FXzZPSGxOR2JyNk40T3RKU2JzcVREOWxxR1B0MDdtekJ2dnRsYXRBVm9tRzRrdmI4YlpZNHBGVEFud3hVUTlBVDduWHFGVXFrRXlHMHJ4RWc3dlpLeWpEdVNvTER6WUVxV1hLMUNPYzNnb0RwYjJQYXZkbUlpZHpfc3p1bmZ6Tmk5YVFQNzBZQkZBc3RMTWlKeFNOOUljOU9LU3IzUVA0bC04bTZmamVrc1lGN1VUZllnamI0XzVsZU1Va3hLOXBFRnBLQk5RMVHSAe8BQVVfeXFMTzM3WGV1TW92ZFd4OFlOMHJjQ3BoNlFLN01aeUZLa3BjS25SQW56X05aOUxGdFFCVzFPTnN3TndTMXA4eFdlTG9xMGNpelBhMmQ5Tkk1QjZZYXZRMmlzMS05VjA3T08wV3lNUFMwY0k2dHJOUktOUEtmOWY4XzdVY2Rpc1hfLWJvYlBoOHNHamRRLThaTERWMXh5eVVmN1ZtcUROX01HNDNZWTF2RUkxWGk4cHJxaURkSzJhVEF1SVdpaEhPNU9La1FzMXNpcy1Ea1NoREhOS0U3RVVRVkZJUmo1WlhjZGs2U1czYlAwdVE?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol Medical AB (publ) publishes interim report, January \u2013 March 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQWE5nSjNNUGhNVUZYN1E0dV9fVWMyQXJmQ2FCMHBKc2dtcHZ2cEs1Tk9laExXN1l0Q2stYklMLVFadTl0VWdRWW9JdEJmQ1RVOHY3cmw3NFdPNWJCMDcyVU5yN3l4MVhRY2Z1bXd4bTN6LXZiTmFvNjR4SEFwSG00cFp6X0ZQYU15RzFuVjgwYm9HaU5DdzRoRkw0VW9SaDczRWJYMERVTWxMelhUdDZDZ3MxNmtOZkNIX0d2QWpJYVdQMzRGb1RsMUpCekQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol secures license for arfolitixorin in autism", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPNWZFSVBTc3JKZ3E4akpKSVZtLTNQbTZlMGI5bW5tTUVfcVViekNJNmpkMzhNWlFvNlJBRlozeEVSUUdERExXbVR3TkJhd3ZKajdrSUxSR1dNanpPaGFuaEc3MUR4S1dGN3BhLXRJTXJwb3REZEJ2cnEySDc3MTZoWkYtdndiNDFlZmc?oc=5", "source_name": "Biostock", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong preliminary phase Ib/II data from Isofol enables tumour surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQdUw2blBsV3FFZnE1aGZtMHQxRkFaNjNuSFpjOFdLNXFTZXJkSnctZ0dYWEl3eVh0aUFxRjFoeWNta1dIdzc3N2tFcW1oeWNBcGwyc1A1S0lsM09sZGJ4LUpJRGlBMURYVUxOcmU4Q1pZZ1l1OGd3U3RiYlAtQVpwcmJYa2U2dHU3dGYtM0JwYk1aYnR4em5FOW03T3E4UXBTRHc?oc=5", "source_name": "Biostock", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dose increase and strengthened cash flow in focus for Isofol Medical", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZXVXd0YteGk4VlQ1MnpZX1Q1RnF3S3NMZGQyRDYzUGpMOFQ0LWxyaGJHelJsYWNOUHJUYVBFUUp2blY1Z28weWJiRWNEdG5qODlkMU9MMHV1UEdxS1pOUHpEU3JCdGpOMmhqVXJBSlhBNnZrM3MtVzU2WGtHTnlINTNQcDFLbFdTLXBERWdOZFRrc3M?oc=5", "source_name": "Biostock", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Patent Office gives green light for Isofol\u2019s arfolitixorin", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPc1QtbGlRZF9DMjlnSUV3aWR3TUNJZHA5QzRtOTlUR0ZFUXFZY2J5LWxkVk1oU1J4MVBaS1FrbXhtVy04VUg1dE9Ka3JIVWxwRGFjQy1UY2t1NjA2YmdpRUFrTEs3Q2luYmdySmVKVlBsWnhmWnlwM01DVVkydVZkT3ZVX0g0ajNLOW1sMHVaU19nOFJ5bjZERmFIU04?oc=5", "source_name": "Biostock", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol reaches new phase Ib/II milestones in Europe \u2013 prepares Japanese study with Solasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ2xnQ19oeUZCZmVCQVFZRHRZd3FabTQwcnR2VE5US1RWbkZ3QklCVzNEWkl5SDRHcGVoUlZaLWlmT3hOVHF5OFpqRmhYckhCLVNtWUw0djZEVlJxM2plM3NoQUU5MjBVYkRvbE92d2ZNWWF0YzhiSHYzOW9xU1h0UVVTWm94M2wzdnh5VXp2Skpvc1p1OU1ROU1PRW1pcjFwUUV0RjdybjlKYWJtWklnZ0c0UUdFMFlhVG1sNDRMWDJRdw?oc=5", "source_name": "Biostock", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Green Light for Higher Doses in Isofol\u2019s Arfolitixorin Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPR1BYbEhud3BCTkFYVTRnS21zYVhnZU13Y1FSb0dRRDlEaGtnM3c5U1FCUmNHdWczQ3REZ0FSWlZlOHBNb0dFb1ptdWVKSWpyUzBWQVM3b0x1ME5hTV9GZzZ3T1BkZ0VpSjhGMFh6aDhodDltdWdSWXRhcVA4amxkdVM4SU8ybm1DekxmQlN1aGwwTEE?oc=5", "source_name": "Biostock", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Isofol begins final dose cohort on the way to Phase II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQcWJ1Vm9TeFVmOFpZNjc3b3FEMGNJSzl2V2NaLVBxZF90X3BvQXJUVHJZX1g2Sk1uN21QUGRnWGNad0E5dlFQR1ZGa04yZ1NVaVM1dy1jOWkzZ3AyM0lMVHRYVnNJZGN0Q3BTVy1oM3pVUWlvUTd6c2phSk5EdXlsZzg2OGtrTWJlMXc?oc=5", "source_name": "Biostock", "published_at": "2026-07-08T15:21:02+00:00", "published_display": "08 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol advances arfolitixorin trial with final dose cohort in colorectal cancer study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQTFJhVkRKSGV1NVlpbHNfOFdMWEZxNlhRYS1SSkpxMl9QMjQzU1JZZERSQU8xdWRYRHM2WXRPOVRFYldYcGZLWHlOOHlwY2hKMXlCdFBfV2hrUExDcGc5d051WWFzRlRvQnlGenY3T1dqbnBCTjhsWXNlOGlkSEZxREZfNGJHRjlEaThSVHduMFZlUzAtNUw3VV81aDBZM2xMd293YXJEdk5DcmpVRGh6UFFtTjlPUTlMd2JHR0ZWRUVUVkhIR3gzXzVTcGNVUmlqZkpN?oc=5", "source_name": "TipRanks", "published_at": "2026-07-08T10:07:10+00:00", "published_display": "08 Jul 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Isofol Medical (STO:ISOFOL) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol Medical AB (publ) publishes interim report, January \u2013 March 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQWE5nSjNNUGhNVUZYN1E0dV9fVWMyQXJmQ2FCMHBKc2dtcHZ2cEs1Tk9laExXN1l0Q2stYklMLVFadTl0VWdRWW9JdEJmQ1RVOHY3cmw3NFdPNWJCMDcyVU5yN3l4MVhRY2Z1bXd4bTN6LXZiTmFvNjR4SEFwSG00cFp6X0ZQYU15RzFuVjgwYm9HaU5DdzRoRkw0VW9SaDczRWJYMERVTWxMelhUdDZDZ3MxNmtOZkNIX0d2QWpJYVdQMzRGb1RsMUpCekQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol secures license for arfolitixorin in autism", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPNWZFSVBTc3JKZ3E4akpKSVZtLTNQbTZlMGI5bW5tTUVfcVViekNJNmpkMzhNWlFvNlJBRlozeEVSUUdERExXbVR3TkJhd3ZKajdrSUxSR1dNanpPaGFuaEc3MUR4S1dGN3BhLXRJTXJwb3REZEJ2cnEySDc3MTZoWkYtdndiNDFlZmc?oc=5", "source_name": "Biostock", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong preliminary phase Ib/II data from Isofol enables tumour surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQdUw2blBsV3FFZnE1aGZtMHQxRkFaNjNuSFpjOFdLNXFTZXJkSnctZ0dYWEl3eVh0aUFxRjFoeWNta1dIdzc3N2tFcW1oeWNBcGwyc1A1S0lsM09sZGJ4LUpJRGlBMURYVUxOcmU4Q1pZZ1l1OGd3U3RiYlAtQVpwcmJYa2U2dHU3dGYtM0JwYk1aYnR4em5FOW03T3E4UXBTRHc?oc=5", "source_name": "Biostock", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dose increase and strengthened cash flow in focus for Isofol Medical", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZXVXd0YteGk4VlQ1MnpZX1Q1RnF3S3NMZGQyRDYzUGpMOFQ0LWxyaGJHelJsYWNOUHJUYVBFUUp2blY1Z28weWJiRWNEdG5qODlkMU9MMHV1UEdxS1pOUHpEU3JCdGpOMmhqVXJBSlhBNnZrM3MtVzU2WGtHTnlINTNQcDFLbFdTLXBERWdOZFRrc3M?oc=5", "source_name": "Biostock", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Patent Office gives green light for Isofol\u2019s arfolitixorin", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPc1QtbGlRZF9DMjlnSUV3aWR3TUNJZHA5QzRtOTlUR0ZFUXFZY2J5LWxkVk1oU1J4MVBaS1FrbXhtVy04VUg1dE9Ka3JIVWxwRGFjQy1UY2t1NjA2YmdpRUFrTEs3Q2luYmdySmVKVlBsWnhmWnlwM01DVVkydVZkT3ZVX0g0ajNLOW1sMHVaU19nOFJ5bjZERmFIU04?oc=5", "source_name": "Biostock", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Isofol reaches new phase Ib/II milestones in Europe \u2013 prepares Japanese study with Solasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQ2xnQ19oeUZCZmVCQVFZRHRZd3FabTQwcnR2VE5US1RWbkZ3QklCVzNEWkl5SDRHcGVoUlZaLWlmT3hOVHF5OFpqRmhYckhCLVNtWUw0djZEVlJxM2plM3NoQUU5MjBVYkRvbE92d2ZNWWF0YzhiSHYzOW9xU1h0UVVTWm94M2wzdnh5VXp2Skpvc1p1OU1ROU1PRW1pcjFwUUV0RjdybjlKYWJtWklnZ0c0UUdFMFlhVG1sNDRMWDJRdw?oc=5", "source_name": "Biostock", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Green Light for Higher Doses in Isofol\u2019s Arfolitixorin Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPR1BYbEhud3BCTkFYVTRnS21zYVhnZU13Y1FSb0dRRDlEaGtnM3c5U1FCUmNHdWczQ3REZ0FSWlZlOHBNb0dFb1ptdWVKSWpyUzBWQVM3b0x1ME5hTV9GZzZ3T1BkZ0VpSjhGMFh6aDhodDltdWdSWXRhcVA4amxkdVM4SU8ybm1DekxmQlN1aGwwTEE?oc=5", "source_name": "Biostock", "published_at": "2025-10-01T07:00:00+00:00", "published_display": "01 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 66, "total_relevant": 10, "sentiment_summary": {"positive": 2, "negative": 0, "neutral": 8, "score": 53, "total": 10, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 2, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.83, "latest_week": "2026-07-10", "one_week_move": 2.5, "four_week_move": 20.1, "twelve_week_move": 13.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.617481, "market_dynamics_buy_signal": false, "relative_strength": 1.949487, "fair_value_gap": -32.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.1573, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.5% over one week, +20.1% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Biostock", "count": 7}, {"label": "TipRanks", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 8}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.5% over one week, +20.1% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Isofol begins final dose cohort on the way to Phase II"}], "updated_at": "2026-07-18T00:33:00.039938+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}